Human Recombinant Relaxin Reduces Heart Injury and Improves Ventricular Performance in a Swine Model of Acute Myocardial Infarction

: This study shows that relaxin can be effective in the treatment of acute myocardial infarction. In a swine model of heart ischemia‐reperfusion currently used to test cardiotropic drugs because of its similarities with human myocardial infarction, human recombinant relaxin (2.5 and 5 μg/kg body wei...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2005-05, Vol.1041 (1), p.431-433
Main Authors: PERNA, AVIO-MARIA, MASINI, EMANUELA, NISTRI, SILVIA, BANI SACCHI, TATIANA, BIGAZZI, MARIO, BANI, DANIELE
Format: Article
Language:English
Subjects:
Animals
cardioprotection
Coronary Vessels - drug effects
Coronary Vessels - physiopathology
Disease Models, Animal
Heart
Heart Ventricles - drug effects
Heart Ventricles - physiopathology
Human
Humans
Injuries
Injury prevention
ischemia
Myocardial infarction
Myocardial Infarction - drug therapy
Myocardial Infarction - pathology
Myocardial Infarction - physiopathology
Performance enhancement
Recombinant
Recombinant Proteins - therapeutic use
Relaxin - therapeutic use
reperfusion
Swine
Ventricular Function
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: This study shows that relaxin can be effective in the treatment of acute myocardial infarction. In a swine model of heart ischemia‐reperfusion currently used to test cardiotropic drugs because of its similarities with human myocardial infarction, human recombinant relaxin (2.5 and 5 μg/kg body weight), given at reperfusion after a 30‐min ischemia, markedly reduced the main serum markers of myocardial damage (myoglobin, CK‐MB, and troponin T) and the metabolic and histopathologic parameters of myocardial inflammation and cardiomyocyte injury, resulting in overall improvement of ventricular performance (increased cardiac index) compared to the controls. These results provide a background for future clinical trials with human relaxin as adjunctive therapy to catheter‐based coronary angioplasty in patients with acute myocardial infarction.
ISSN:0077-8923
1749-6632
DOI:10.1196/annals.1282.064